Loading...

ANVS ANNOVIS BIO INC Earnings Reports 8-K Filing

NNVS

NVS

ANNOVIS BIO INC

(ANVS)

2024 8-K

Quarterly Earnings Report

Stock Offering Announcement

Management Change

Earnings Report

Webinar Announcement

Earnings Report

Stock Offering Update

New Stock Offering

Management Change

Management Change

Contract Renewal

NYSE Compliance Notice

Financial Results

Alzheimer's Study Start

Public Offering

Investor Presentation

Earnings Report

Management Change

Financial Results

FDA Meeting Update

Financial Results

Preclinical Data Announcement

FDA Approval for New Crysta...

Announcement of Phase III P...

Annual Meeting Results

Positive Drug Results and W...

Financial Results Announcement

Departure of CFO

Stock Purchase Agreement

Earnings Reports

Securities Offering

Agreement with Institutiona...

Regulation FD Disclosure

Securities Offering

Agreement with Institutiona...

Public Offering

Annual Meeting Approval

Dismissal of Independent Re...

Termination of Sales Agreement

Equity Offering

Earnings Reports

Phase 3 Clinical Trial Results

Restatement of Financial St...

External Links:

Annovis Bio Inc reported a net loss of $5.1 million for the third quarter of 2023, with cash and cash equivalents totaling $12.2 million as of September 30, 2023.

AI Assistant

ANNOVIS BIO INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.